SOPH SOPHiA GENETICS S.A.: שווי פעילות לרווח לפני ריבית, מסים ופחת
SOPHiA GENETICS SA (SOPH) develops cloud IT solutions for precision medicine, leveraging external server capacities and remote support to drive global growth. This chart of historical price action reflects that the EV/EBITDA currently stands at 0.00. SOPHiA GENETICS SA (SOPH) maintains its market position due to the complexity of clinics switching to alternative software and its AI-driven therapy selection. The network effect expands the competitive moat: the more data the platform processes, the more valuable it becomes for physicians.
פילוחי מדדים ואנליטיקה של חברת sophiagenetics.com (SOPH)
SOPHiA GENETICS SA is developing cloud-based AI data analysis for clinical genomics, leveraging an extensive database of patient profiles. The EV/EBITDA multiple dynamics for this capital-intensive enterprise reflect the total enterprise value, including debt, relative to operating income before depreciation and amortization. This ratio allows for an assessment of the company's actual capital revaluation during periods of market consolidation. A decline in this metric to historical lows signals that the asset is undervalued, yet warns of potential business stagnation risks.
